| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 308.52M | 351.41M | 442.74M | 410.60M | 413.75M | 389.52M |
| Gross Profit | 277.75M | 343.86M | 442.74M | 409.18M | 412.23M | 298.32M |
| EBITDA | 80.02M | 100.24M | -924.87M | 261.44M | 233.33M | 141.90M |
| Net Income | -7.88M | 880.00K | -1.00B | 175.06M | 528.45M | 106.18M |
Balance Sheet | ||||||
| Total Assets | 342.95M | 350.91M | 471.07M | 1.10B | 1.13B | 559.24M |
| Cash, Cash Equivalents and Short-Term Investments | 92.85M | 88.56M | 92.15M | 656.20M | 620.13M | 362.56M |
| Total Debt | 598.67M | 599.48M | 715.54M | 415.92M | 475.80M | 453.70M |
| Total Liabilities | 651.11M | 652.24M | 817.37M | 448.14M | 521.02M | 496.60M |
| Stockholders Equity | -308.16M | -301.33M | -346.30M | 652.38M | 605.91M | 62.64M |
Cash Flow | ||||||
| Free Cash Flow | 29.94M | 103.41M | 183.15M | 273.63M | 261.63M | 166.99M |
| Operating Cash Flow | 29.98M | 103.55M | 183.43M | 273.76M | 261.89M | 168.84M |
| Investing Cash Flow | -65.00K | -142.00K | -1.03B | -136.00K | -265.00K | -1.84M |
| Financing Cash Flow | -41.95M | -106.97M | 277.16M | -237.55M | -4.55M | 18.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $1.11B | 34.08 | 16.16% | ― | 22.61% | -63.00% | |
| ― | $2.04B | ― | -2.82% | ― | 38.68% | -160.14% | |
| ― | $1.22B | ― | -9.28% | ― | 26.66% | -419.55% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $976.84M | ― | -15.57% | ― | 2.25% | -301.59% | |
| ― | $269.64M | ― | ― | ― | -22.98% | -173.28% | |
| ― | $1.44B | ― | -16.34% | ― | -1.03% | 8.13% |
On October 7, 2025, Andrew Dreyfus announced his resignation from the Board of Directors of Ironwood Pharmaceuticals, Inc., effective November 1, 2025. His departure is due to his new role as President and CEO of the National Institute for Health Care Management Foundation and is not related to any disagreements with Ironwood Pharmaceuticals. The company expressed gratitude for his contributions during his tenure.
The most recent analyst rating on (IRWD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
On August 29, 2025, Ironwood Pharmaceuticals announced it has regained compliance with Nasdaq’s minimum bid price requirement, following a previous notice of non-compliance on May 28, 2025. This compliance ensures the company’s continued inclusion on the Nasdaq Global Select Market, marking a positive development for its market positioning.
The most recent analyst rating on (IRWD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases, with a notable product, LINZESS, for treating irritable bowel syndrome with constipation and chronic idiopathic constipation.